Anguk Sitagliptin Tablet 100 mg (Sitagliptin Phosphate Hydrate)
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Anguk Pharmaceutical Co., Ltd.
MFDS item code 201503242 · Approved 2015.05.28
This product's status changed to Expired on 2025.05.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used alongside diet and exercise to help control blood sugar in patients with type 2 diabetes. It can be administered alone to patients starting diabetes treatment, and when blood sugar control is inadequate with monotherapy, it can be used in conjunction with metformin. Additionally, for patients already using sulfonylureas, metformin, thiazolidinediones, or insulin alone but not achieving sufficient blood sugar control, this medication can be combined to enhance therapeutic effects. If blood sugar control remains challenging despite combining with metformin and other diabetes medications, this medication can also be added. It helps manage blood sugar effectively in this variety of treatment regimens.
This medicine is administered at a dose of 100 mg once daily as monotherapy or combination therapy, with a maximum daily dose of 100 mg. This medicine may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.
This medication is used for the treatment of diabetes and helps with blood sugar control. However, serious allergic reactions may occur while taking this medication; therefore, if symptoms such as a skin rash, difficulty breathing, or swelling of the face or lips occur, discontinue use immediately and consult a physician. Furthermore, this medication may cause pancreatitis, an inflammation of the pancreas, so if symptoms such as abdominal pain, vomiting, or nausea appear, you must inform your healthcare provider immediately. This medication should not be taken by patients with type 1 diabetes, diabetic ketoacidosis, or those allergic to this medication or any component of it. Patients with reduced kidney function may require dosage adjustment, and regular kidney function testing before and after administration is important. The risk of hypoglycemia may increase when this medication is combined with other diabetes treatments, so dosage adjustments may be necessary if taken with insulin or sulfonylureas. Side effects such as headache, upper respiratory infection, nasopharyngitis, diarrhea, nausea, etc., may occur during treatment; if symptoms are severe or persistent, consult a physician. It is advisable for women who are pregnant or nursing to avoid using this medication, and safety and efficacy in children and adolescents under 18 years of age have not been established. Caution is advised for the elderly due to the potential for decreased kidney function, and regular kidney function tests are recommended. In cases of overdose, general treatment should be initiated, and some can be removed via hemodialysis; therefore, follow the instructions of medical personnel. Inform your doctor immediately if skin blisters or sores occur during treatment, and consider discontinuing the medication if severe joint pain develops. Finally, this medication is known not to significantly impact cardiovascular safety; however, if any abnormal symptoms occur during administration, consult your healthcare provider.
Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, hypoglycemia, nasopharyngitis, upper respiratory tract infection, headache, diarrhea, abdominal pain, nausea, peripheral edema, dyspepsia, dizziness, elevated liver enzymes, acute kidney failure, constipation, vomiting, severe joint pain accompanied by disability, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, pneumonia, diabetes complications, metabolic acidosis, falls, cardiac arrest, increased blood triglycerides, gastritis, weight loss, hypertension, hypernatremia, erectile dysfunction
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture ingress. It is recommended to maintain storage temperature between 1 to 30 degrees Celsius.
Beige, round, biconvex film-coated tablet
In-house packaging unit
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Anguk Pharmaceutical Co., Ltd.

Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Sitagliptin Phosphate Hydrate 32.13mg
Tablet · Prescription medication
Jong Kundang Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Sinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.